Logo

US FDA Granted Fast Track Designation to Medicure’s MC-1 for PNPO deficiency

Share this

US FDA Granted Fast Track Designation to Medicure’s MC-1 for PNPO deficiency

Shots:

  • US FDA granted Fast Track designation to Medicure’s MC-1 for seizures associated with PNPO deficiency. Also received Rare Pediatric Disease Designation and ODD by US FDA; ODD by EMA
  • Medicure is in launch phase of P-III study, daily dose of MC-1 will be administered to approx. 10 PNPO patients in US and Australia
  • If FDA approves NDA for MC-1, Medicure will receive Priority Review voucher which can be redeemed or sold

Ref: Medicure | Image: Medicure

Related News:- Takeda’s Entyvio Receives the US FDA’s Approval for Subcutaneous Administration to Treat Moderately to Severely Active Crohn’s Disease (CD)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions